High dose therapy for light chain amyloidosis: can we reduce treatment related mortality further?
Dimopoulos
Meletios
M
Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece. mdimop@med.uoa.gr
Kastritis
Efstathios
E
D000686:Amyloidosis / Q000401:mortality / Q000628:therapy*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000401:mortality; D006801:Humans; D007147:Immunoglobulin Light Chains; D018579:Patient Selection; D015996:Survival Rate; D014182:Transplantation, Autologous
D000970:Antineoplastic Agents; D007147:Immunoglobulin Light Chains